Madison-based Exact Sciences Corp. reported revenues of $48.4 million for the first quarter of 2017 compared to $14.8 million for the same period in 2016.
The company completed about 100,000 Cologuard at-home tests for colon cancer during the quarter.
The company has raised its 2017 projections and now anticipates revenue of $195–$205 million and at least 470,000 completed Cologuard tests this year.
Previous projections were $170–$180 million in revenue and at least 415,000 completed tests.
Advertisement
